Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 |
| NCT04202835 | ATG Plus PTCy vs ATG for CGVHD Prophylaxis | active not recruiting | Phase 2 | 80 | McMaster UniversityOTHER | 2 | May 11, 2025 | clinicaltrials |
| NCT02646839 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | enrolling by invitation | Phase 2 | 50 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04232241 | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | active not recruiting | Phase 2 | 167 | Universitätsklinikum Hamburg-EppendorfOTHER | 7 | Apr 22, 2025 | clinicaltrials |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial(MAST) | recruiting | Phase 2 | 50 | Imperial College LondonOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06900088 | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06892223 | Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation | recruiting | Phase 2 | 42 | Istituto Clinico HumanitasOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04741945 | Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS | recruiting | Phase 2 | 40 | Kirsten GrønbækOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06664970 | A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor | enrolling by invitation | Phase 2 | 39 | Peking Union Medical College HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06598969 | TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia(TMLI-MA) | not yet recruiting | Phase 2 | 58 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602323 | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.(TMLI-RI) | not yet recruiting | Phase 2 | 34 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06536959 | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | recruiting | Phase 2 | 67 | Beijing 302 HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen(SoraGVL) | recruiting | Phase 2 | 88 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT(VitaStem) | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06046313 | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | recruiting | Phase 2 | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | recruiting | Phase 2 | 200 | Karolinska University HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05025098 | Precision Therapy Versus Standard Therapy in AML and MDS in Elderly(PALM) | recruiting | Phase 2 | 36 | University Hospital, AkershusOTHER | 1 | Aug 27, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 18, 2025source: clinicaltrials